Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib/II clinical trial of AMY-101 in patients with the rare diseases C3G (C3 glomerulopathy).

Next Previous
X
Search
Trial Profile

A phase Ib/II clinical trial of AMY-101 in patients with the rare diseases C3G (C3 glomerulopathy).

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMY 101 (Primary)
  • Indications Membranous glomerulonephritis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 18 Dec 2017 New trial record
    • 13 Dec 2017 According to a Amyndas Pharmaceuticals media release, company is now planning to initiate Phase Ib/II clinical trials in patients with the rare diseases C3G and PNH for which AMY-101 has received orphan designation from the FDA and the EMA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top